Research report · Public share

巨子生物

HK · 02367 · 2026-10-30 · Full research
Neutral
Investment opportunityfair_low观察期权而非错杀:净现金+理财73.96亿元占市值40.7%、PB 1.94x上市最低、trailing股息率7.07%构成下行垫,但以珀莱雅2026E约11.2x同业锚倒推现价19.65港元隐含归母约16.2亿元、与本run基准16.5-17.5亿元大体一致——市场无显著错误定价,机会成立须由盈利企稳证据逐项兑现(双11绝对GMV/排名、FY2026费用率回落联立DTC增速、派息维持62-67%),基准公允区间21-24港元(较锚+7%~+22%),验证前不宜按反转逻辑配置。
How was this report? Leave anonymous feedback.
This report was generated automatically by Loyan AI. For research reference only — not investment advice.
Want a research assistant that never forgets and challenges its own views?
Sign in to add this research to your library, or register for free to get started.
Sign in / register free
巨子生物 · Full research — Loyan AI Research Partner